Comparative Pharmacology
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus OGEN 2 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus OGEN 2 5.
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL vs OGEN 2.5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethynodiol diacetate is a progestin that suppresses gonadotropin secretion (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and increases cervical mucus viscosity, impeding sperm penetration.
Estrogen replacement therapy; binds to estrogen receptors, leading to activation of estrogen-responsive genes and physiological effects mimicking endogenous estrogens.
1 tablet (1 mg ethynodiol diacetate / 35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days.
0.625 mg orally once daily (estropipate 0.75 mg equivalent), cyclic or continuous.
None Documented
None Documented
Ethynodiol diacetate: 12-14 hours; ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady-state achieved after 3-4 days.
10-24 hours; terminal half-life may be prolonged in hepatic impairment.
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites). Ethynodiol diacetate is extensively metabolized; less than 1% excreted unchanged.
Primarily renal as sulfate and glucuronide conjugates; less than 10% excreted unchanged.
Category D/X
Category C
Estrogen
Estrogen